HROW - Harrow: Buy A Blend Of Value And Growth
2025-09-12 10:57:55 ET
Introduction & Investment Thesis
I am bullish on Harrow, Inc. ( HROW ) driven by the VEVYE Access for All program . This program has introduced cyclosporine ophthalmic solution for a dry eye condition by making it accessible and affordable for more patients at a discounted price. Patients eligible for this offer are spending a maximum of $59 per bottle. Without insurance, access to cyclosporine ophthalmic has averaged around $773.64 for a 1-month single-use vial. With Harrow, this price has been reduced to $59 under insurance after partnering with PhilRX. Patients eligible for this program can now access discounted prices through physicians sending VEVYE prescriptions to PhilRx....
Harrow: Buy A Blend Of Value And Growth